Assenagon Asset Management S.A. Lowers Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Assenagon Asset Management S.A. reduced its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 67.8% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,405 shares of the biopharmaceutical company's stock after selling 13,513 shares during the period. Assenagon Asset Management S.A.'s holdings in Alnylam Pharmaceuticals were worth $1,729,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Whipplewood Advisors LLC grew its holdings in Alnylam Pharmaceuticals by 208.8% during the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 71 shares during the last quarter. Larson Financial Group LLC grew its position in shares of Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 73 shares during the last quarter. Park Square Financial Group LLC bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $28,000. Colonial Trust Co SC bought a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at approximately $35,000. Finally, OFI Invest Asset Management bought a new position in Alnylam Pharmaceuticals in the 4th quarter worth approximately $35,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Yvonne Greenstreet sold 19,297 shares of the company's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the transaction, the chief executive officer now owns 48,948 shares in the company, valued at approximately $14,978,088. This represents a 28.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.20% of the company's stock.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY traded up $3.61 during midday trading on Wednesday, reaching $312.32. 981,185 shares of the company were exchanged, compared to its average volume of 931,264. The stock's 50-day moving average price is $273.09 and its 200-day moving average price is $259.83. The stock has a market cap of $40.72 billion, a P/E ratio of -149.44 and a beta of 0.22. The company has a quick ratio of 2.98, a current ratio of 3.04 and a debt-to-equity ratio of 8.88. Alnylam Pharmaceuticals, Inc. has a one year low of $152.30 and a one year high of $322.98.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. The business's revenue for the quarter was up 20.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.16) earnings per share. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ALNY has been the subject of a number of research reports. Chardan Capital increased their price target on shares of Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Wall Street Zen downgraded Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday. William Blair restated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Royal Bank Of Canada lifted their price target on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an "outperform" rating in a research note on Friday, March 21st. Finally, UBS Group upped their target price on shares of Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $319.58.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.